Search Result

Results for "

cardiomyocyte hypertrophy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) AMPK (2) Amyloid-β (2) Anion Exchangers (1) Apoptosis (4) Autophagy (2) c-Met/HGFR (1) Carbonic Anhydrase (1) DGK (1) Drug Derivative (1) EGFR (1) Endogenous Metabolite (2) Endothelin Receptor (1) Environmental Pollutants (1) ERK (2) Ferroptosis (1) G Protein-coupled Receptor Kinase (GRK) (3) GSK-3 (2) Guanylate Cyclase (1) HDAC (2) HSP (1) Interleukin Related (1) JAK (1) JNK (1) Keap1-Nrf2 (1) KLF (2) Mitochondrial Metabolism (2) mTOR (1) Na+/H+ Exchanger (NHE) (1) NF-κB (1) NO Synthase (1) Oxidative Phosphorylation (1) p38 MAPK (1) PI3K (2) PKD (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Salt-inducible Kinase (SIK) (2) SARS-CoV (1) SGLT (1) SOD (1) Src (1) STAT (2) Succinate Receptor 1 (1) TNF Receptor (1) Virus Protease (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (16) Endocrinology (2) Infection (1) Inflammation/Immunology (4) Metabolic Disease (5) Neurological Disease (4)

By Targets:

Akt (3)

AMPK (2)

Amyloid-β (2)

Anion Exchangers (1)

Apoptosis (4)

Autophagy (2)

c-Met/HGFR (1)

Carbonic Anhydrase (1)

DGK (1)

Drug Derivative (1)

EGFR (1)

Endogenous Metabolite (2)

Endothelin Receptor (1)

Environmental Pollutants (1)

ERK (2)

Ferroptosis (1)

G Protein-coupled Receptor Kinase (GRK) (3)

GSK-3 (2)

Guanylate Cyclase (1)

HDAC (2)

HSP (1)

Interleukin Related (1)

JAK (1)

JNK (1)

Keap1-Nrf2 (1)

KLF (2)

Mitochondrial Metabolism (2)

mTOR (1)

Na+/H+ Exchanger (NHE) (1)

NF-κB (1)

NO Synthase (1)

Oxidative Phosphorylation (1)

p38 MAPK (1)

PI3K (2)

PKD (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

Salt-inducible Kinase (SIK) (2)

SARS-CoV (1)

SGLT (1)

SOD (1)

Src (1)

STAT (2)

Succinate Receptor 1 (1)

TNF Receptor (1)

Virus Protease (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (16)

Endocrinology (2)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (5)

Neurological Disease (4)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W017113

2-Mercaptobenzothiazole 1 Publications Verification	Environmental Pollutants Endogenous Metabolite	Metabolic Disease
2-Mercaptobenzothiazole is an activator of the aryl hydrocarbon receptor (AhR) , inhibiting thyroid hormone synthesis and dopamine beta-hydroxylase activity . 2-Mercaptobenzothiazole promotes bladder cancer cell invasion by altering the conformation of the AhR ligand binding domain (LBD), activating AhR transcription, and upregulating the mRNA and protein expression of target genes CYP1A1 and CYP1B1 . 2-Mercaptobenzothiazole inhibits thyroid peroxidase (TPO) with an IC₅₀ value of 11.5 μM, induces histological changes such as follicular cell hypertrophy in Xenopus laevis tadpoles, delaying metamorphosis . 2-Mercaptobenzothiazole increases chromosomal aberrations and sister chromatid exchanges (SCEs) in Chinese hamster ovary (CHO) cells, and enhances carcinogenicity in F344/N rats . 2-Mercaptobenzothiazole inhibits norepinephrine synthesis in mice and completely blocks the conversion of exogenous dopamine to norepinephrine in rat cardiomyocytes .

HY-168438

ERBB agonist-1 1 Publications Verification	EGFR Akt ERK	Cardiovascular Disease
ERBB agonist-1 (Compound EF-1) is an agonist for ERBB4, that activates the ERBB4 signaling pathway by inducing dimerization of the ERBB4 receptor with an EC₅₀ of 10.5 μM. ERBB agonist-1 induces phosphorylation of Akt and ERK1/2, reduces the collagen expression in cardiac fibroblasts, inhibits H₂O₂-induced cardiomyocyte death and Ang II (HY-13948)-induced cardiomyocyte hypertrophy. ERBB agonist-1 prevents fibrosis and exhibits cardioprotective efficacy in mouse models .

HY-143248

KR-39038 1 Publications Verification	G Protein-coupled Receptor Kinase (GRK) HDAC	Cardiovascular Disease
KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC₅₀ of 0.02 μM. KR-39038 significantly inhibits angiotensin II-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research .

HY-N1570

Pterosin B	Salt-inducible Kinase (SIK) KLF Amyloid-β	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Pterosin B is an orally active indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .

HY-168894

CT-1	Ferroptosis JAK STAT p38 MAPK AMPK GSK-3 Apoptosis HSP TNF Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
CT-1 is a secreted protein belonging to the IL-6 cytokine family. Overexpression of CT-1 enhances cell proliferation, migration and angiogenesis via the ADMA/DDAH pathway. CT-1 inhibits the growth of triple-negative breast cancer cells by simultaneously inducing Ferroptosis in N2-type tumor-associated neutrophils and cancer cells. CT-1 activates the Jak/STAT-3, p42/p44 MAPK and AMPK pathways, and inhibits GSK-3β activity through phosphorylation to induce cardiomyocyte hypertrophy. CT-1 enhances the viability of cardiomyocytes and neurons, reduces cell Apoptosis, induces the expression of heat shock proteins (HSP) and BNP, and inhibits TNF levels. CT-1 exerts anti-tumor activity in mouse models of triple-negative breast cancer. CT-1 improves cognitive impairment in mice. CT-1 is applicable to the research of ischemic heart disease, triple-negative breast cancer, myocardial hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment and diabetes-related cognitive impairment .

HY-141552

FC9402 2 Publications Verification	Mitochondrial Metabolism	Cardiovascular Disease
FC9402 is a potent and selective sulfide quinone oxidoreductase (SQOR) inhibitor extracted from patent WO 2020/146636 A1. FC9402 attenuates TAC-induced cardiomyocyte hypertrophy and left ventricle (LV) fibrosis. FC9402 can be used for cardiovascular regulation .

HY-W042301

Xipamide	Anion Exchangers Carbonic Anhydrase Endothelin Receptor	Cardiovascular Disease
Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na ⁺/Cl ^--potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl ^-/NaCO₃ ^- anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca ²⁺ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites .

HY-N1910

4'-O-Methylbavachalcone 4 Publications Verification	SARS-CoV Virus Protease Succinate Receptor 1 ERK	Infection Neurological Disease
4'-O-Methylbavachalcone is an orally active prenylated flavonoid that inhibits the activity of SARS-CoV papain-like protease (PLpro), with an IC₅₀ of 10.1 μM and a K_i of 4.6 μM. 4'-O-Methylbavachalcone inhibits poly (ADP-ribose) polymerase-mediated cell death (parthanatos), reduces cerebral infarct volume, binds to the orthosteric site of SUCNR1, blocks the interaction between succinate and SUCNR1, inhibits SUCNR1 activity, blocks the nuclear translocation of NFATc4, suppresses the activation of the ERK1/2 signaling pathway, inhibits cardiomyocyte hypertrophy and restores the expression of α-actinin. 4'-O-Methylbavachalcone can be used in studies related to ischemic stroke, SARS-CoV and cardiomyocyte hypertrophy .

HY-118052

BPKDi	PKD HDAC	Cardiovascular Disease
BPKDi is an inhibitor of PKD. BPKDi inhibits three members of the PKD family, PKD1, PKD2, and PKD3, with IC₅₀ values of 1 nM, 9 nM, and 1 nM, respectively. BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes and concomitantly suppresses hypertrophy of these cells .

HY-174400

SGLT2-IN-2	SGLT SOD Na+/H+ Exchanger (NHE) Autophagy	Cardiovascular Disease
SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice .

HY-149453

MCUF-651	Guanylate Cyclase	Cardiovascular Disease
MCUF-651 is an orally active guanylyl cyclase A receptor (GC-A) positive allosteric modulator (PAM) (K_D: 397 nM ). MCUF-651 binds to GC-A and selectively enhances the binding of atrial natriuretic peptide (ANP) to GC-A. MCUF-651 enhances ANP-mediated cGMP generation in human cardiac, renal, and fat cells. MCUF-651 inhibits cardiomyocyte hypertrophy .

HY-160706

HHQ16	Drug Derivative	Cardiovascular Disease
HHQ16 is an orally active derivative of Astragaloside IV (HY-N0431). HHQ16 effectively reverses infarction-induced hypertrophy and heart failure by targeted degrading lnc4012/lnc9456 and antagonizing their effects on G3BP2/NF-κB signaling .

HY-122949

Momordicine I 2 Publications Verification	Apoptosis Autophagy DGK Mitochondrial Metabolism NO Synthase PI3K Akt Interleukin Related Src AMPK mTOR NF-κB c-Met/HGFR STAT Keap1-Nrf2 Reactive Oxygen Species (ROS) Oxidative Phosphorylation Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Momordicine I is a cucurbitane-type triterpenoids. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. Momordicine I inhibits glycolysis, lipid metabolism, induces autophagy in HNC cells to suppress head and neck cancer growth. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ. Momordicine I exerts its cardiovascular benefits by upregulating nitric oxide, inhibiting the activity of angiotensin-converting enzyme (ACE), activating the PI3K/Akt pathway, reducing oxidative stress and inflammation. Momordicine I inhibits AKT1, IL-6, and SRC, suggesting its potential application in type 2 diabetes .

HY-N1570R

Pterosin B (Standard)	Reference Standards Salt-inducible Kinase (SIK) KLF Amyloid-β	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Pterosin B (Standard) is the analytical standard of Pterosin B (HY-N1570). This product is intended for research and analytical applications. Pterosin B is an indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .

HY-173005

JZ19	PI3K Akt GSK-3 Apoptosis	Cardiovascular Disease
JZ19 reduces the LDH and ROS levels, and exhibits antioxidant activity against oxygen-glucose deprivation (OGD)-induced cardiomyocyte injury. JZ19 reverses Isoproterenol (HY-B0468)-induced cardiomyocyte hypertrophy and apoptosis through PI3K-AKT-GSK3β signaling pathway. JZ19 alleviates Isoproterenol (HY-B0468)-induced heart failure in mouse models .

HY-169052

Cyy-272	JNK Apoptosis	Cardiovascular Disease Inflammation/Immunology
Cyy-272 is an orally active JNK inhibitor with IC₅₀ values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 can be used in the study of obese cardiomyopathy .

HY-120718

CCG 224061	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
CCG 224061 is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with a IC₅₀ of 0.066 μM. CCG 224061 inhibits GRK activity in cardiomyocytes . CCG 224061 is applicable to research related to heart disease, heart failure, myocardial hypertrophy and hypertension .

HY-120168

CCG 258001	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
CCG 258001 is a GRK inhibitor with IC₅₀ values of 0.29, 51.8, and 33 µM against GRK2, GRK1, and GRK5, respectively. CCG 258001 inhibits GRK activity in cardiomyocytes and other muscle cells. CCG 258001 is applicable to the research of heart diseases, including heart failure, myocardial hypertrophy, and hypertension .

Cat. No.	Product Name	Category	Target	Chemical Structure